Bausch Health asserts push to 'vigorously' defend Xifaxan patent litigation
Bausch Health will continue litigating over its Xifaxan drug, threatening to appeal all the way up to the US Court of Appeals for the Federal Circuit.
The Quebec-based company, through its gastroenterology business Salix Pharmaceuticals, said it will file an appeal if the final order is consistent with an oral order in a Delaware district court last week centered around a case against Norwich Pharmaceuticals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.